低分子肝素对老年冠心病患者凝血机制的影响

目的　探讨老年冠心病患者使用低分子肝素的安全性。方法　观察24例老年冠心病成功进行PTCA术后及51例对照组使用低分子肝素(速避凝)10000ICUAXa，每日2次共10d后出血情况及凝血机制改变。结果　用药后两组出血情况、其它脏器合并症及凝血时间测定等均无明显差异，老年组血浆纤维蛋白原(FBI)较对照组明显增高(4.69±1.36，3.95±1.01，P＜0.05)，对照组治疗后FBI较治疗前明显降低(3.95±1.01，3.33±0.41，P＜0.05)。结论　老年人应用较大剂量低分子肝素具有相对好的安全性。

The influence of lowmolecular weight heparin on blood coagulability in elderly patients with coronary heartdisease

Objective In order to find the security of low molecular weightheparin used in elderly patients with coronary heart diseas e(CHD).Methods We observed the bleeding and blood coagubility(PL T,PT and APTT) in 24 elderly patients with CHD who were performed percutaneous t ransluminal coronary angioplasty and 51 young man controls with CHD,after hypode rm ical injection of low molecular weight heparin 10 000 ICUAXa twice a day for 10 days.Results There was no significant difference between t he e lderly and the controls in bleeding,complication.PLT,PT and APTT.FIB was higher in the elderly patients than in the young controls(4.69±1.36 vs 3.95±1.01 ，P＜0.05).FIB decreased apparently(3.95±1.01 vs 3.33±0.41，P＜0 .05)in the young controls after treatment.Conclusions These data suggest that elderly patients may have more serious coagulation.It is secure that elderly patients use low molecular weight heparin.